Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.

https://doi.org/10.1182/hematology.2019000075

Published: 2019

Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.

https://doi.org/10.1182/hematology.2019000032

Published: 2019

Journal Articles

Molecular profiling and management of mantle cell lymphoma

Jia Ruan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 30–40.

https://doi.org/10.1182/hematology.2019000011

Published: 2019

Journal Articles

Treatments targeting MDS genetics: a fool’s errand?

Amy E. DeZern

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 277–285.

https://doi.org/10.1182/asheducation-2018.1.277

Published: 2018

Journal Articles

Novel immunotherapy approaches to follicular lymphoma

Christopher R. Flowers, John P. Leonard, Loretta J. Nastoupil

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 194–199.

https://doi.org/10.1182/asheducation-2018.1.194

Published: 2018

Journal Articles

Treatment approach for young, fit, newly diagnosed multiple myeloma patients

Saad Z. Usmani, Eric Seifter

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 97–102.

https://doi.org/10.1182/asheducation-2018.1.97

Published: 2018

Journal Articles

Current treatment algorithm for the management of lower-risk MDS

Aristoteles Giagounidis

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 453–459.

https://doi.org/10.1182/asheducation-2017.1.453

Published: 2017

Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.

https://doi.org/10.1182/asheducation-2017.1.212

Published: 2017

Journal Articles

Management of multiple myeloma in the relapsed/refractory patient

Pieter Sonneveld

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 508–517.

https://doi.org/10.1182/asheducation-2017.1.508

Published: 2017

Journal Articles

Myeloma: management of the newly diagnosed high-risk patient

Angela Dispenzieri

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 485–494.

https://doi.org/10.1182/asheducation-2016.1.485

Published: 2016

Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.

https://doi.org/10.1182/asheducation-2016.1.495

Published: 2016

Journal Articles

Role of stem cell transplant and maintenance therapy in plasma cell disorders

Philip L. McCarthy, Sarah A. Holstein

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 504–511.

https://doi.org/10.1182/asheducation.V2016.1.504.088352

Published: 2016

Journal Articles

Treatment of low-risk myelodysplastic syndromes

Valeria Santini

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 462–469.

https://doi.org/10.1182/asheducation-2016.1.462

Published: 2016

Journal Articles

Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

Hetty E. Carraway

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 470–477.

https://doi.org/10.1182/asheducation-2016.1.470

Published: 2016

Journal Articles

Maintenance therapy for multiple myeloma in the era of novel agents

Thierry Facon

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 279–285.

https://doi.org/10.1182/asheducation-2015.1.279

Published: 2015

Journal Articles

Novel combination approaches for myeloma

Sagar Lonial, Ajay K. Nooka

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 286–293.

https://doi.org/10.1182/asheducation-2015.1.286

Published: 2015

Journal Articles

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Amy E. DeZern

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 308–316.

https://doi.org/10.1182/asheducation-2015.1.308

Published: 2015

Journal Articles

Multiple myeloma: a model for scientific and clinical progress

Jesus San Miguel

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 1–7.

https://doi.org/10.1182/asheducation-2014.1.1

Published: 2014

Journal Articles

Therapeutic targeting of microenvironment in follicular lymphoma

Grzegorz S. Nowakowski, Stephen M. Ansell

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 169–173.

https://doi.org/10.1182/asheducation-2014.1.169

Published: 2014

Journal Articles

Established and novel agents for myelodysplastic syndromes

Mikkael A. Sekeres, Aaron T. Gerds

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 82–89.

https://doi.org/10.1182/asheducation-2014.1.82

Published: 2014

NARROW

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Indolent lymphomas: pushing the pace with novel agents

Molecular profiling and management of mantle cell lymphoma

Treatments targeting MDS genetics: a fool’s errand?

Novel immunotherapy approaches to follicular lymphoma

Treatment approach for young, fit, newly diagnosed multiple myeloma patients

Current treatment algorithm for the management of lower-risk MDS

Fixed duration vs continuous therapy in multiple myeloma

Management of multiple myeloma in the relapsed/refractory patient

Myeloma: management of the newly diagnosed high-risk patient

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Role of stem cell transplant and maintenance therapy in plasma cell disorders

Treatment of low-risk myelodysplastic syndromes

Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

Maintenance therapy for multiple myeloma in the era of novel agents

Novel combination approaches for myeloma

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Multiple myeloma: a model for scientific and clinical progress

Therapeutic targeting of microenvironment in follicular lymphoma

Established and novel agents for myelodysplastic syndromes

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only